329
Participants
Start Date
November 16, 2020
Primary Completion Date
November 10, 2022
Study Completion Date
November 10, 2022
Beovu
There is no treatment allocation. Patients administered Beovu by prescription that have started before inclusion of the patient into the study were enrolled.
Novartis Investigative Site, Nagoya
Novartis Investigative Site, Nagoya
Novartis Investigative Site, Nagoya
Novartis Investigative Site, Nagoya
Novartis Investigative Site, Nagoya
Novartis Investigative Site, Toyohashi
Novartis Investigative Site, Urayasu
Novartis Investigative Site, Iizuka
Novartis Investigative Site, Kurume
Novartis Investigative Site, Kure
Novartis Investigative Site, Hakodate
Novartis Investigative Site, Hakodat
Novartis Investigative Site, Sapporo
Novartis Investigative Site, Kakogawa-shi
Novartis Investigative Site, Kobe
Novartis Investigative Site, Kobe
Novartis Investigative Site, Nishinomiya
Novartis Investigative Site, Ishioka
Novartis Investigative Site, Mito
Novartis Investigative Site, Kanazawa
Novartis Investigative Site, Kita-gun
Novartis Investigative Site, Yokohama
Novartis Investigative Site, Yokosuka
Novartis Investigative Site, Kumamoto
Novartis Investigative Site, Yokkaichi
Novartis Investigative Site, Kesennuma
Novartis Investigative Site, Sendai
Novartis Investigative Site, Sendai
Novartis Investigative Site, Miyakonojō
Novartis Investigative Site, Matsumoto
Novartis Investigative Site, Nagasaki
Novartis Investigative Site, Kashihara
Novartis Investigative Site, Okayama
Novartis Investigative Site, Nakagami
Novartis Investigative Site, Urazoe
Novartis Investigative Site, Hirakata
Novartis Investigative Site, Moriguchi
Novartis Investigative Site, Osaka
Novartis Investigative Site, Ōsaka-sayama
Novartis Investigative Site, Sakai
Novartis Investigative Site, Suita
Novartis Investigative Site, Iruma-gun
Novartis Investigative Site, Saitama-shi
Novartis Investigative Site, Ohtsu-city
Novartis Investigative Site, Ohtsu-city
Novartis Investigative Site, Oda
Novartis Investigative Site, Hamamatsu
Novartis Investigative Site, Izunokuni
Novartis Investigative Site, Shizuoka
Novartis Investigative Site, Shimotsuke
Novartis Investigative Site, Bunkyo Ku
Novartis Investigative Site, Bunkyo Ku
Novartis Investigative Site, Chiyoda-ku
Novartis Investigative Site, Hachiōji
Novartis Investigative Site, Musashino
Novartis Investigative Site, Shinjuku Ku
Novartis Investigative Site, Shinjuku-ku
Novartis Investigative Site, Akita
Novartis Investigative Site, Fukuoka
Novartis Investigative Site, Fukuoka
Novartis Investigative Site, Fukuoka
Novartis Investigative Site, Fukuoka
Novartis Investigative Site, Hiroshima
Novartis Investigative Site, Kyoto
Novartis Investigative Site, Nagasaki
Novartis Investigative Site, Okayama
Novartis Investigative Site, Osaka
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY